SCHEMBL16010952

SCHEMBL16010952

CC(C)C1=CC(=O)[C@H]2C(C)(C)CCC[C@@]12C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.54
CYP3A4 P08684 4/20 0.35
USP2 O75604 3/20 0.35
MAPT P10636 3/20 0.35
TP53 P04637 2/20 0.35
HSP90AA1 P07900 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
FDPS P14324 4/20 0.34
ALDH1A1 P00352 2/20 0.33
HSD17B10 Q99714 1/20 0.33
GGPS1 O95749 2/20 0.33
CYP19A1 P11511 2/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA7 P36544 1/20 0.33
CHRNA4 P43681 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14882079 1.00 EP300 (0.54) EP300CYP3A4USP2MAPTTP53
SCHEMBL11447483 0.77 EP300 (0.48) EP300CYP3A4USP2MAPTALDH1A1
SCHEMBL14881442 0.77 EP300 (0.48) EP300CYP3A4USP2MAPTALDH1A1
SCHEMBL16010773 0.77 EP300 (0.48) EP300CYP3A4USP2MAPTALDH1A1
SCHEMBL14882167 0.77 EP300 (0.38) EP300CYP3A4USP2MAPTTP53
SCHEMBL14880141 0.76 EP300 (0.40) EP300CYP3A4USP2MAPTTP53
SCHEMBL14879678 0.76 EP300 (0.40) EP300CYP3A4USP2MAPTTP53
SCHEMBL16010777 0.73 EP300 (0.45) EP300CYP3A4USP2MAPTTP53
SCHEMBL14881395 0.73 EP300 (0.45) EP300CYP3A4USP2MAPTTP53
SCHEMBL16010973 0.73 EP300 (0.45) EP300CYP3A4USP2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2768307-B1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE BIKAM PHARMACEUTICALS INC (US) 2020-03-18 EP claimed
US-9499464-B2 Opsin-binding ligands, compositions and methods of use BIKAM PHARMACEUTICALS, INC. (US) 2016-11-22 US claimed
US-20140256782-A1 Opsin-Binding Ligands, Compositions and Methods of Use BIKAM PHARMACEUTICALS, INC. (US) 2014-09-11 US claimed
EP-2768307-B1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE BIKAM PHARMACEUTICALS INC (US) 2020-03-18 EP disclosed
US-20170137398-A1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE BIKAM PHARMACEUTICALS, INC. (US) 2017-05-18 US disclosed
US-9499464-B2 Opsin-binding ligands, compositions and methods of use BIKAM PHARMACEUTICALS, INC. (US) 2016-11-22 US disclosed
US-20140256782-A1 Opsin-Binding Ligands, Compositions and Methods of Use BIKAM PHARMACEUTICALS, INC. (US) 2014-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137398-A1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE CRYAB, CRYAA, PDE6C EP300 4044/4885CYP3A4 4427/4885USP2 4166/4885
US-20140256782-A1 Opsin-Binding Ligands, Compositions and Methods of Use CRYAB, PDE6C, CRYAA EP300 4137/4885CYP3A4 4349/4885USP2 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.